[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342388-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342388-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mesenchymalepithelial-transition-and-axl-inhibitor-tp-0903-sensitise-triple-negative-breast-cancer-cells-to-the-antimalarial-compound-artesunate","Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate","","Triple-negative breast cancer (TNBC) is an aggressive disease lacking estrogen, progesterone, and HER2 receptors, leaving limited targeted options and contributing to poor overall and relapse-free survival. EMT-driven programs promote drug resistance and metastasis, motivating strategies that induce reverse mesenchymal–epithelial transition (MET). This study shows that the ROS-generating antimalarial artesunate is more cytotoxic in epithelial than mesenchymal breast cancer cells, and that MET induction by the clinically relevant AXL inhibitor TP-0903 synergizes with artesunate to enhance ROS accumulation, DNA damage, and apoptosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mesenchymalepithelial-transition-and-axl-inhibitor-tp-0903-sensitise-triple-negative-breast-cancer-cells-to-the-antimalarial-compound-artesunate/342388/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mesenchymalepithelial-transition-and-axl-inhibitor-tp-0903-sensitise-triple-negative-breast-cancer-cells-to-the-antimalarial-compound-artesunate/342388.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is TNBC difficult to treat compared with other breast cancer subtypes?","Question",{"text":63,"@type":64},"TNBC lacks estrogen, progesterone, and HER2 receptors, so receptor-targeted therapies used in other subtypes are not applicable. Limited targeted options and EMT-associated resistance contribute to poorer outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the study connect EMT/MET programs to drug sensitivity?",{"text":68,"@type":64},"The document describes EMT and reverse MET as reversible differentiation programs. Inducing MET can shift tumor cells toward an epithelial state, sensitizing them to therapies effective for epithelial tumors.",{"name":70,"@type":61,"acceptedAnswer":71},"What role do TP-0903 and artesunate play in the reported cellular effects?",{"text":72,"@type":64},"Artesunate generates ROS and shows higher cytotoxicity in epithelial than mesenchymal cell lines. The AXL inhibitor TP-0903 induces MET and synergizes with artesunate, increasing ROS, DNA damage, and apoptotic cell death in TNBC cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342388,1790145835,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMesenchymal–epithelial transition and AXL inhibitor TP‑0903 sensitise triple‑negative breast cancer cells to the antimalarial compound, artesunate  \nMirko Terragno1*, AnastassiyaVetrova1, Oleg Semenov2, A. Emre Sayan3, Marina Kriajevska1,4 & Eugene Tulchinsky1,4*  \nTriple‑negative breast cancer (TNBC) is a difficult‑to‑treat, aggressive cancer type. TNBC is often associated with the cellular program of epithelial‑mesenchymal transition (EMT) that confers drug resistance and metastasis. EMT and reverse mesenchymal‑epithelial transition (MET) programs are regulated by several signaling pathways which converge on a group of transcription factors, EMT‑ TFs. Therapy approaches could rely on the EMT reversal to sensitise mesenchymal tumours to compounds effective against epithelial cancers. Here, we showthatthe antimalarial ROS‑generating compound artesunate (ART) exhibits higher cytotoxicity in epithelial than mesenchymal breast cancer cell lines. Ectopic expression of EMT‑TF ZEB1 in epithelial or ZEB1 depletion in mesenchymal cells, respectively, reduced or increased ART‑generated ROS levels, DNA damage and apoptotic cell death. In epithelial cells, ZEB1 enhanced expression of superoxide dismutase 2 (SOD2) and glutathione peroxidase 8 (GPX8) implicated in ROS scavenging. Although SOD2 or GPX8 levels were unaffected in mesenchymal cells in response to ZEB1 depletion, stable ZEB1 knockdown enhanced total ROS. Receptor tyrosine kinaseAXL maintains a mesenchymal phenotype and is overexpressed inTNBC. The clinically‑relevant AXL inhibitor TP‑0903 induced MET and synergised with ART to generate ROS, DNA damage and apoptosis inTNBC cells. TP‑0903 reduced the expression of GPX8 and SOD2. Thus, TP‑0903 and ZEB1 knockdown sensitisedTNBC cells to ART, likely via different pathways. Synergistic interactions between TP‑0903 and ART indicate that combination approaches involving these compounds can have therapeutic prospects forTNBC treatment.  \nTriple-negative breast cancer (TNBC), by definition, lacks the expression of estrogen, progesterone, and HER2 receptors. Therefore, therapies targeting these receptors, which are effective in receptor-positive breast cancer subtypes, cannot be applied to TNBC. Currently, no targeted therapy approaches are designed specifically for TNBC. Surgery, chemotherapy, and radiation are the only methods for treating these patients 1. Because of the drug resistance, rapid recurrence, and high metastatic propensity, women with TNBC have much lower overall and relapse-free survival than other breast cancer patients2. There is an urgent need to develop new approaches to treat this cancer type. On the molecular level, TNBC is highly heterogeneous and includes at least six molecular subtypes3. Most TNBC fit in basal-like, BL1 (Basal-Like 1) and BL2 (Basal-Like 2) or mesenchymal ML (Mesenchymal-Like) and MSL (Mesenchymal/Stem-Like) categories4,5. Two mesenchymal-like groups, MLand MSL, constitute a most dedifferentiated claudin-low subtype. This subtype is closely related to metaplastic breast cancer which is characterised by chemoresistance, worse survival and features of epithelial-mesenchymal transition (EMT)6.  \nEMT and a process of mesenchymal-epithelial transition (MET) are reversible differentiation programs operating at different stages of embryonic development. Elements of these programs are hijacked by metastatic  \n1Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana, Kazakhstan. 2Regulation of Gene Expression Laboratory, Institute of Cytology RAS, Saint Petersburg, Russia. 3Cancer Sciences Division, University of Southampton, Southampton, UK. 4Department of Genetics and Genome Biology, University of  \nLeicester, Leicester, UK.*[email: mirko.terragno@nu.edu.kz](email: mirko.terragno@nu.edu.kz); [eugene.tulchinsky@nu.edu.kz](eugene.tulchinsky@nu.edu.kz); [et32@le.ac.uk](et32@le.ac.uk)  \n[www. nature.","cbCaihjskimuNdf3","https://ap.wps.com/l/cbCaihjskimuNdf3","pdf",4121393,12,"English","# Introduction\n## Triple-negative breast cancer and treatment challenges\n## EMT/MET plasticity and transcriptional control\n## AXL signaling as a therapeutic target","[{\"question\":\"Why is TNBC difficult to treat compared with other breast cancer subtypes?\",\"answer\":\"TNBC lacks estrogen, progesterone, and HER2 receptors, so receptor-targeted therapies used in other subtypes are not applicable. Limited targeted options and EMT-associated resistance contribute to poorer outcomes.\"},{\"question\":\"How does the study connect EMT/MET programs to drug sensitivity?\",\"answer\":\"The document describes EMT and reverse MET as reversible differentiation programs. Inducing MET can shift tumor cells toward an epithelial state, sensitizing them to therapies effective for epithelial tumors.\"},{\"question\":\"What role do TP-0903 and artesunate play in the reported cellular effects?\",\"answer\":\"Artesunate generates ROS and shows higher cytotoxicity in epithelial than mesenchymal cell lines. The AXL inhibitor TP-0903 induces MET and synergizes with artesunate, increasing ROS, DNA damage, and apoptotic cell death in TNBC cells.\"}]","Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate | PDF",1790046390,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7abb6e21692ec81389125d858c7707e6.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30eaad3f388380af7392ff430cd977fb.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1cc98e14a375498aa7253264ee44cf1.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37e10e45399b50ffa9f066326c48c555.webp",980,1287]